Abstract
Stereotactic body radiotherapy (SBRT) has emerged as a potential treatment approach for recurrent head and neck cancers, but its role remains controversial. This concise clinical perspective summarizes the current evidence on SBRT for recurrent head and neck cancers and discusses key considerations regarding appropriate patient selection, treatment planning, toxicity risks, and combination with other therapies. The author concludes that SBRT may provide benefits for select recurrent head and neck cancer patients, but more research is still needed to determine optimal use.